Stock Track | Legend Biotech Plummets 5% as Analysts Cut Price Targets Following Q1 Results

Stock Track

May 14, 2025

Shares of Legend Biotech (LEGN) plummeted 5.02% in Wednesday's trading session following multiple analyst price target cuts in response to the company's recent first-quarter results. The biotech firm, known for its cell therapy developments, faced a significant market reaction as investors digested the revised outlooks.

Truist Securities lowered its price target for Legend Biotech from $88 to $71, while RBC cut its target from $84 to $78. Despite these reductions, both firms maintained their Buy ratings on the stock, indicating continued confidence in the company's long-term prospects. The average price target now stands at $76.87, according to FactSet data, still suggesting potential upside from current levels.

The price target cuts appear to be driven by concerns stemming from Legend Biotech's Q1 performance, particularly regarding Carvykti, the company's flagship CAR-T cell therapy. However, the maintained Buy ratings suggest that analysts believe in the company's overall strategy and growth potential. As Legend Biotech continues to navigate the competitive landscape of cell therapy, investors will be closely watching for signs of improved performance in the coming quarters.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1103616343"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1103616343\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1103616343?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-14 22:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1103616343","market":"hk","top_or_hot":-1,"title":"Stock Track | Legend Biotech Plummets 5% as Analysts Cut Price Targets Following Q1 Results","media":"Stock Track","content":"<p>Shares of Legend Biotech (LEGN) plummeted 5.02% in Wednesday's trading session following multiple analyst price target cuts in response to the company's recent first-quarter results. The biotech firm, known for its cell therapy developments, faced a significant market reaction as investors digested the revised outlooks.</p>\n\n<p>Truist Securities lowered its price target for Legend Biotech from $88 to $71, while RBC cut its target from $84 to $78. Despite these reductions, both firms maintained their Buy ratings on the stock, indicating continued confidence in the company's long-term prospects. The average price target now stands at $76.87, according to FactSet data, still suggesting potential upside from current levels.</p>\n\n<p>The price target cuts appear to be driven by concerns stemming from Legend Biotech's Q1 performance, particularly regarding Carvykti, the company's flagship CAR-T cell therapy. However, the maintained Buy ratings suggest that analysts believe in the company's overall strategy and growth potential. As Legend Biotech continues to navigate the competitive landscape of cell therapy, investors will be closely watching for signs of improved performance in the coming quarters.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Legend Biotech Plummets 5% as Analysts Cut Price Targets Following Q1 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Legend Biotech Plummets 5% as Analysts Cut Price Targets Following Q1 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-05-14 22:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Legend Biotech (LEGN) plummeted 5.02% in Wednesday's trading session following multiple analyst price target cuts in response to the company's recent first-quarter results. The biotech firm, known for its cell therapy developments, faced a significant market reaction as investors digested the revised outlooks.</p>\n\n<p>Truist Securities lowered its price target for Legend Biotech from $88 to $71, while RBC cut its target from $84 to $78. Despite these reductions, both firms maintained their Buy ratings on the stock, indicating continued confidence in the company's long-term prospects. The average price target now stands at $76.87, according to FactSet data, still suggesting potential upside from current levels.</p>\n\n<p>The price target cuts appear to be driven by concerns stemming from Legend Biotech's Q1 performance, particularly regarding Carvykti, the company's flagship CAR-T cell therapy. However, the maintained Buy ratings suggest that analysts believe in the company's overall strategy and growth potential. As Legend Biotech continues to navigate the competitive landscape of cell therapy, investors will be closely watching for signs of improved performance in the coming quarters.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LEGN","symbol_name":"传奇生物","start_time":0,"source_url":"","article_id":"1103616343","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1103616343","pubTimestamp":1747231251,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Legend Biotech  plummeted 5.02% in Wednesday's trading session following multiple analyst price target cuts in response to the company's recent first-quarter results. The biotech firm, known for its cell therapy developments, faced a significant market reaction as investors digested the revised outlooks.Truist Securities lowered its price target for Legend Biotech from $88 to $71, while RBC cut its target from $84 to $78. Despite these reductions, both firms maintained their Buy rating","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LEGN":"传奇生物"},"translate_title":"分析师在第一季度业绩公布后下调目标价，传奇生物股价暴跌5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LEGN":1},"content_text":"Shares of Legend Biotech (LEGN) plummeted 5.02% in Wednesday's trading session following multiple analyst price target cuts in response to the company's recent first-quarter results. The biotech firm, known for its cell therapy developments, faced a significant market reaction as investors digested the revised outlooks.\nTruist Securities lowered its price target for Legend Biotech from $88 to $71, while RBC cut its target from $84 to $78. Despite these reductions, both firms maintained their Buy ratings on the stock, indicating continued confidence in the company's long-term prospects. The average price target now stands at $76.87, according to FactSet data, still suggesting potential upside from current levels.\nThe price target cuts appear to be driven by concerns stemming from Legend Biotech's Q1 performance, particularly regarding Carvykti, the company's flagship CAR-T cell therapy. However, the maintained Buy ratings suggest that analysts believe in the company's overall strategy and growth potential. As Legend Biotech continues to navigate the competitive landscape of cell therapy, investors will be closely watching for signs of improved performance in the coming quarters.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}